Overbevisende evidens for reduktion af komplikationer til type 2-diabetes ved intensiv antihypertensiv behandling

Ugeskrift for Laeger

Volumn 161, Issue 34, 1999, Pages 4764-

  Hansen, Klavs Würgler ^a   Poulsen, Per Løgstrup ^a   Mogensen, Carl Erik ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR FUNCTION; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CONTROLLED CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 0033598099     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (10)

1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
3. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised study. Lancet 1998; 35: 1755-62.
4. Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ et al. The systolic hypertension in europe trial investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-84.
5. Gäde P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-22.
6. Guidelines subcommittee. 1999 World Health Organization- International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83.
7. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20.
8. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A. Captopril Prevention Project study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-16.
9. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Eng J Med 1998; 338: 645-53.
10. Tatti P, Pahor M, Byington RP, Di Mauro PD, Guarisco R, Strollo G et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomised Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.